Aperture Therapeutics is advancing APRTX-003, an RNA-based antisense therapy targeting MMP9, as a potential ALS treatment.

Mindwalk identified TDP-43 antibodies that selectively target abnormal protein clumps linked to ALS and other diseases.

Currently, the MyoRegulator® device is under investigation as a non-invasive treatment for ALS in a second and larger clinical trial, the CALM ( C ontrolling A myotrophic L ateral Sclerosis M otor ...

A pharmaceutical company based in New Jersey that’s known for its FDA-approved treatment for ALS is set to be acquired for $2.5 billion. Tanabe Pharma America, which operates a U.S. headquarters in ...

PALO ALTO, Calif.--(BUSINESS WIRE)--Neuvivo, a late-clinical stage biopharmaceutical company, today announced promising results from two groundbreaking publications on its investigational ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has approved RELYVRIO™ ...

LOS ANGELES, Nov. 4, 2025 /PRNewswire/ -- Spinogenix, Inc., a clinical-stage biopharmaceutical company pioneering first-in-class therapeutics designed to restore synapses to improve health in the ...

Some evidence reports natural medications, such as Wugongtang and Dihuangyinzi, may help slow the progression of ALS or Lou Gehrig’s disease. However, they cannot cure it. Amyotrophic lateral ...

(RTTNews) - NeuroSense Therapeutics Ltd. (NRSN), on Monday, announced a binding term sheet with a global pharmaceutical company to accelerate the development and commercialization of PrimeC, its ...

TOKYO, Oct 16, 2024 - (JCN Newswire) - - Eisai Co., Ltd. announced today that amyotrophic lateral sclerosis (ALS) treatment "Rozebalamin(R) for Injection 25 mg" (mecobalamin) has received the Good ...